Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Arcturus Therapeutics Holdings (ARCT) EBIT Margin (2018 - 2025)

Historic EBIT Margin for Arcturus Therapeutics Holdings (ARCT) over the last 8 years, with Q3 2025 value amounting to 96.27%.

  • Arcturus Therapeutics Holdings' EBIT Margin fell 705100.0% to 96.27% in Q3 2025 from the same period last year, while for Sep 2025 it was 80.27%, marking a year-over-year decrease of 300600.0%. This contributed to the annual value of 62.81% for FY2024, which is 159300.0% down from last year.
  • Arcturus Therapeutics Holdings' EBIT Margin amounted to 96.27% in Q3 2025, which was down 705100.0% from 41.04% recorded in Q2 2025.
  • Over the past 5 years, Arcturus Therapeutics Holdings' EBIT Margin peaked at 75.77% during Q4 2022, and registered a low of 2711.14% during Q1 2021.
  • In the last 5 years, Arcturus Therapeutics Holdings' EBIT Margin had a median value of 81.53% in 2022 and averaged 557.64%.
  • As far as peak fluctuations go, Arcturus Therapeutics Holdings' EBIT Margin crashed by -23535500bps in 2021, and later surged by 26031300bps in 2022.
  • Quarter analysis of 5 years shows Arcturus Therapeutics Holdings' EBIT Margin stood at 649.72% in 2021, then skyrocketed by 112bps to 75.77% in 2022, then plummeted by -178bps to 59.22% in 2023, then tumbled by -148bps to 146.68% in 2024, then soared by 34bps to 96.27% in 2025.
  • Its EBIT Margin was 96.27% in Q3 2025, compared to 41.04% in Q2 2025 and 57.27% in Q1 2025.